A large and rigorous randomized clinical trial has delivered compelling evidence that newer classes of blood-thinning medications can substantially reduce serious cardiovascular complications for individuals living with atrial fibrillation who face an intermediate risk of stroke.
The findings, which carry significant implications for global cardiology practices and clinical guidelines, were unveiled during a highly anticipated Hot Line session at the ESC Congress 2026. Simultaneously, the complete data and analysis were published in the New England Journal of Medicine, ensuring worldwide visibility among cardiovascular specialists, researchers, and healthcare policy planners. According to the trial data, treating intermediate-risk patients with oral anticoagulants was definitively associated with a lower incidence of adverse clinical events compared to receiving no anticoagulant therapy at all.
A Gray Area in Atrial Fibrillation Treatment
Atrial fibrillation, commonly known as AF, is one of the most prevalent sustained heart rhythm disorders encountered in clinical practice worldwide. The condition is characterized by an irregular and often rapid heartbeat, which can severely disrupt normal blood flow through the heart chambers. This disruption frequently leads to the formation of blood clots within the heart, which can subsequently travel to the brain and trigger a debilitating or fatal stroke.
Current international medical guidelines, including those issued by the European Society of Cardiology (ESC), provide unambiguous direction for managing patients diagnosed with atrial fibrillation who are categorized as having a high risk of stroke. In those high-risk scenarios, clinical guidelines strongly recommend the immediate and continuous initiation of oral anticoagulants.
However, for a substantial population of patients who fall into an intermediate risk category, the therapeutic landscape has long remained far less definitive. For these individuals, current clinical guidance does not mandate immediate blood thinner therapy; instead, anticoagulant treatment is traditionally listed merely as an option that "should be considered" by treating physicians.
This lingering clinical uncertainty has persisted for years largely because earlier observational research on the subject has produced conflicting and mixed results. Furthermore, much of the historical data relied upon older generations of medications, particularly vitamin K antagonist drugs, which come with complex monitoring requirements and variable patient responses.
Principal Investigator of the SINGLE-AF trial, Professor Boyoung Joung from Yonsei University in Seoul, South Korea, highlighted the historical context and the rationale behind the new study during his presentation. "Evidence from observational studies with anticoagulants, particularly vitamin K antagonists, remains conflicting in those at intermediate risk," Professor Joung explained. "SINGLE-AF was conducted to provide the first evidence from a randomized trial on whether newer direct oral anticoagulants are beneficial in patients with AF at intermediate risk of stroke."
Testing Newer Blood Thinners in a Controlled Setting
To address the longstanding knowledge gap and provide high-quality scientific data, the research team designed and executed the SINGLE-AF trial as an open-label, multi-center study. The trial was successfully carried out across 18 specialized medical centers located throughout South Korea, ensuring rigorous clinical oversight and diverse patient management perspectives.
In total, the researchers enrolled 1,803 individuals diagnosed with atrial fibrillation who were formally evaluated and classified as having an intermediate risk of stroke. For the purposes of this trial, intermediate stroke risk was precisely defined using the widely accepted CHA2DS2-VASc scoring system, corresponding to a score of 1 in male participants and a score of 2 in female participants.
Upon enrollment, the study participants were randomized in a one-to-one ratio to one of two distinct management strategies. The first group of patients received active direct oral anticoagulant treatment, utilizing either apixaban administered at a dose of 5 milligrams twice daily or rivaroxaban administered at a dose of 20 milligrams once daily, depending on clinical evaluations and standard dosing protocols. The second group of participants served as the control arm and received no anticoagulation therapy whatsoever, reflecting the traditional ambiguity surrounding routine treatment for this specific patient subset.
Serious Events Fell by 69% Among Treated Patients
Following a meticulous follow-up period spanning 24 months, the research team analyzed the primary outcomes and uncovered a striking difference between the two study arms. Patients who were assigned to take direct oral anticoagulants experienced a remarkable 69% relative reduction in the trial’s primary endpoint when compared directly against those patients who received no anticoagulation therapy.
The comprehensive primary endpoint established for the trial was carefully constructed to encompass a broad spectrum of severe clinical occurrences, combining stroke, systemic embolism, major bleeding events, and cardiovascular death into a single composite metric.
When looking at the absolute numbers, serious adverse events occurred in only 0.5% of the patients who received direct oral anticoagulant therapy. In stark contrast, serious events were documented in 1.5% of the patients who were assigned to the control group receiving no anticoagulant medication. Statistical analysis confirmed the significance of this finding, yielding a hazard ratio of 0.31 with a 95% confidence interval ranging from 0.10 to 0.94, and a p-value of 0.028.
A deeper examination of the data revealed that this profound clinical benefit was driven largely by a substantial drop in the incidence of ischemic strokes among the treated population. Specifically, an ischemic stroke occurred in just 0.1% of the patients taking direct oral anticoagulants, whereas the incidence rose to 1.1% among the patients who received no anticoagulation therapy.
Of critical importance to clinicians and patients alike, the trial did not find any accompanying increase in the risk of major bleeding—a traditional concern that often leads physicians to hesitate before prescribing blood thinners to intermediate-risk individuals. Major bleeding events were recorded in only 0.3% of the patients who received direct oral anticoagulant therapy, compared to 0.5% of the patients who did not receive any anticoagulation. This demonstrated that the therapeutic benefits of the medication could be achieved safely without exposing patients to an elevated hemorrhage hazard.
Findings Could Influence Future Guidelines and Reimbursement Policies
The publication and presentation of the SINGLE-AF trial results mark a significant milestone in cardiovascular medicine. By providing robust, randomized clinical data where previously only observational and conflicting evidence existed, the study directly addresses a challenging dilemma that physicians face daily in outpatient cardiology clinics.
The results offer strong empirical support for the proactive use of newer blood thinners in a specific group of atrial fibrillation patients whose risk-benefit profile for anticoagulation has historically been difficult to quantify. By demonstrating clear efficacy without a corresponding surge in major bleeding complications, the trial answers lingering safety and efficacy questions that have divided medical opinion for years.
In his concluding remarks at the ESC Congress, Professor Joung emphasized the broader practical implications that these findings hold for the medical community at large. "We now have evidence from a randomized trial that patients with AF at intermediate stroke risk benefit from DOAC therapy, without an increase in major bleeding," Professor Joung stated. He added that the robust data generated by the SINGLE-AF trial are expected to serve as a vital foundation to inform and shape future clinical guideline recommendations and healthcare reimbursement policies globally.